LTCR‑O1‑1
Post‑transplant lymphoproliferative disorders
Pre‑clinicalUpcoming
Key Facts
Indication
Post‑transplant lymphoproliferative disorders
Phase
Pre‑clinical
Status
Upcoming
Company
About Lion TCR
Pioneering mRNA‑based TCR‑T cell immunotherapy for HBV‑driven liver cancer in Asia.
View full company profile